Showing results (41-50 of 114) with videos related to
Sort By:
Pageof 12
Membranes|March 26, 2025
Enhancing the Performance of Tangential Flow Microfiltration for Bioreactor ClarificationAmir Hossein Mostafavi, Liang-Kai Chu, Xianghong Qian, et al.The Journal of Clinical Endocrinology and Metabolism|October 11, 2024
Arterial Stiffness Associated with Long-Term Major Adverse Cardiac Events in Patients of Primary AldosteronismVin-Cent Wu, Wen-Kai Chu, Po-Lung Yang, et al.Human Vaccines & Immunotherapeutics|July 27, 2019
Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in ChinaJialei Hu, Hongguang Li, Kai Chu, et al.Vaccine|August 1, 2020
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 yearsKai Chu, Kangwei Xu, Rong Tang, et al.Infectious Diseases and Therapy|May 3, 2024
Nasal Staphylococcus aureus Carriage and Antimicrobial Resistance Profiles Among Community-Dwelling Adults in Jiangsu, ChinaWenjing Hu, Yang Wang, Lu Zhou, et al.Human Vaccines & Immunotherapeutics|April 30, 2020
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in ChinaYuemei Hu, Ming Shao, Yuansheng Hu, et al.Frontiers in Immunology|October 6, 2023
Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trialJialei Hu, Yueyue Liu, Shuo Liu, et al.Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|December 23, 2022
A difficult-to-treat pleuropulmonary histoplasmosis in a patient with rheumatoid arthritis in TaiwanWen-Kai Chu, Un-In Wu, Tai-Fen Lee, et al.Human Vaccines & Immunotherapeutics|February 3, 2025
Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in ChinaShiyuan Wang, Yang Zhang, Guifan Li, et al.Human Vaccines & Immunotherapeutics|February 20, 2019
Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized studyYuemei Hu, Kai Chu, Nathalie Lavis, et al.Pageof 12